If you’ve been told you have osteoporosis—or you’re watching a parent shrink a little each year—you’ve probably heard about injectable treatments that go beyond the daily pill. The osteoporosis shot represents a genuine new frontier in bone health, offering options that can cut fracture risk by 40–70% depending on the drug and the skeletal site. For patients who can’t tolerate oral bisphosphonates, or whose bone density keeps dropping despite taking them, these injections have changed the game.
There are currently four FDA-approved injectable osteoporosis medications: denosumab (Prolia), teriparatide (Forteo), abaloparatide (Tymlos), and romosozumab (Evenity). Each works through a different mechanism, carries different risks, and suits different clinical scenarios. Below, I’ll walk through exactly how they compare, who should get which shot, and what the fracture data actually shows.
Why Injectable Osteoporosis Treatments Exist
Oral bisphosphonates like alendronate (Fosamax) and risedronate (Actonel) have been the backbone of osteoporosis treatment for decades. They work. But they come with real-world problems: esophageal irritation, the requirement to sit upright for 30–60 minutes after dosing, and poor absorption if taken with food or calcium supplements. Studies show adherence to oral bisphosphonates drops below 50% by one year.
Injectable therapies bypass the GI tract entirely. Some are given every six months in a clinic, others daily at home via a pen device. More critically, certain injectables don’t just slow bone loss—they actually build new bone, something oral bisphosphonates cannot do.
The Four Osteoporosis Shots: Head-to-Head Comparison
| Drug | Brand Name | Mechanism | Dosing | Hip Fracture Risk Reduction | Approximate Annual Cost (US) |
|---|---|---|---|---|---|
| Denosumab | Prolia | RANKL inhibitor (anti-resorptive) | 60 mg SC every 6 months | 40% | $1,800–$2,400 |
| Teriparatide | Forteo | PTH analog (anabolic) | 20 mcg SC daily × 2 years | ~50% (vertebral) | $28,000–$36,000 |
| Abaloparatide | Tymlos | PTHrP analog (anabolic) | 80 mcg SC daily × 2 years | ~43% (non-vertebral) | $24,000–$30,000 |
| Romosozumab | Evenity | Sclerostin inhibitor (dual: anabolic + anti-resorptive) | 210 mg SC monthly × 12 months | 38% (clinical fracture) | $22,000–$26,000 |
How Each Shot Works
Denosumab (Prolia): The Anti-Resorptive Workhorse
Denosumab is a monoclonal antibody that blocks RANK ligand, the signal osteoclasts need to mature and chew through bone. Given as a subcutaneous injection every six months in your doctor’s office, it increases bone mineral density (BMD) at the spine by roughly 9% over three years (FREEDOM trial). It’s the most widely prescribed osteoporosis shot.
The catch: you can’t just stop it. Discontinuing denosumab triggers rapid bone loss and a rebound increase in vertebral fracture risk, sometimes within months. Patients stopping denosumab must transition to a bisphosphonate.
Teriparatide (Forteo) and Abaloparatide (Tymlos): The Bone Builders
These are anabolic agents—they stimulate osteoblasts to lay down new bone rather than simply slowing breakdown. Teriparatide is a synthetic fragment of parathyroid hormone; abaloparatide is a parathyroid hormone-related protein analog. Both are self-injected daily using a pen device, similar to insulin.
Treatment duration is capped at two years due to a theoretical osteosarcoma risk observed in rat studies (at doses 3–58× human equivalents). After completing the course, patients must follow up with an anti-resorptive agent to maintain gains. In the VERO trial, teriparatide reduced new vertebral fractures by 56% compared to risedronate.
Romosozumab (Evenity): The Newest Player
Approved in 2019, romosozumab inhibits sclerostin, a protein that normally puts the brakes on bone formation. The result is a unique dual effect: it both stimulates bone building and reduces bone resorption simultaneously. In the ARCH trial, romosozumab followed by alendronate reduced hip fracture risk by 38% versus alendronate alone.
Romosozumab carries a black-box warning for cardiovascular risk. It’s contraindicated in patients who’ve had a heart attack or stroke within the past year, and clinicians weigh cardiovascular history carefully before prescribing.
Who Is a Candidate for an Osteoporosis Shot?
Not everyone with low bone density needs an injectable. These medications are generally reserved for:
- High fracture risk: T-score ≤ −2.5 at the hip or spine, or a prior fragility fracture
- Oral bisphosphonate failure: Continued bone loss or new fractures despite ≥1 year of compliant oral therapy
- GI intolerance: Esophagitis, GERD, or Barrett’s esophagus preventing oral bisphosphonate use
- Very high-risk patients: Multiple vertebral fractures, T-score ≤ −3.0, or high FRAX score—these patients may benefit from starting with an anabolic agent first (“anabolic-first” strategy)
- Glucocorticoid-induced osteoporosis: Teriparatide has shown superiority over alendronate in this population
Diagnosis: How Bone Health Is Measured
Before starting any osteoporosis shot, your doctor will order a DEXA scan (dual-energy X-ray absorptiometry), which measures bone mineral density at the hip and lumbar spine. Results are reported as a T-score:
- Above −1.0: Normal
- −1.0 to −2.5: Osteopenia (low bone mass)
- −2.5 or below: Osteoporosis
Your provider may also check serum calcium, vitamin D (25-OH), PTH levels, and bone turnover markers (CTX for resorption, P1NP for formation) to guide treatment selection and monitor response.
When to See a Doctor
Don’t wait for a fracture. Schedule a bone health evaluation if you:
- Are a postmenopausal woman or a man over 50 with risk factors
- Have lost more than 1.5 inches of height
- Have taken prednisone or equivalent for 3+ months
- Sustained a fracture from a low-impact fall (standing height or less)
- Have a parent who fractured a hip
If you’re already on oral bisphosphonates and still losing bone density, ask your provider specifically about injectable options and whether an anabolic-first approach makes sense for your risk level.
Frequently Asked Questions
How painful is the osteoporosis shot?
Denosumab and romosozumab are standard subcutaneous injections—comparable to a flu shot. Teriparatide and abaloparatide use small-gauge pen needles similar to insulin pens, and most patients rate the discomfort as minimal after the first few days.
Can I stop the osteoporosis shot once my bone density improves?
It depends on the drug. Anabolic agents (teriparatide, abaloparatide, romosozumab) are time-limited by design and must be followed by an anti-resorptive. Denosumab should never be stopped abruptly—doing so can cause rebound vertebral fractures within 6–12 months. A transition plan is essential.
Are there serious side effects?
Rare but real risks include osteonecrosis of the jaw (ONJ) and atypical femur fractures with long-term denosumab use—though incidence is roughly 1–10 per 100,000 patient-years. Romosozumab’s cardiovascular warning is the most significant safety concern among the injectables. Hypocalcemia can occur with denosumab if calcium and vitamin D levels aren’t optimized beforehand.
Which osteoporosis shot is best?
There’s no single “best” shot. For very high-risk patients, current guidelines increasingly favor starting with an anabolic agent (romosozumab or teriparatide) and then switching to an anti-resorptive—this sequence builds bone first, then locks in the gains. For moderate-risk patients intolerant of oral pills, denosumab is the most practical option.
Does insurance cover osteoporosis injections?
Most Medicare Part B and commercial plans cover denosumab with relatively low copays. Anabolic agents are significantly more expensive, and prior authorization is almost always required. Manufacturer patient assistance programs exist for all four drugs and can reduce out-of-pocket costs substantially.
